Arvinas, Inc.

NASDAQ:ARVN

Biotechnology

Healthcare
$6.77 -1.30%

-$0.10 today

Market cap
$443.01M
Beta
1.75
P/E (TTM)
-2.2
EPS (TTM)
-$3.46
52W Low $6.06High $14.51

Volume 1.09M

Average 0.89M

ARVN Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Arvinas, Inc.NASDAQ: ARVN

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares declines year over year

Q1 FY2026 weighted avg shares of 64M shares fell 11.7% year over year, behind the -4.9% change in trailing-twelve-month weighted avg shares. Sequentially, it fell 1.4% from the prior quarter. Over 3 fiscal years it compounded at +6.9% a year.

Context

  • Weighted avg shares increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -11.7% toward the trailing-twelve-month pace of -4.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
64M-1.4% QoQ
Last fiscal yearDec 2025
64.9M-9.7% YoY
LTMMar 2026
68.65M-4.9% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-11.7%——
1 year-9.7%——
3-year CAGR+6.9%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
64.9M USD
Year-over-year change
-9.7%
4-year CAGR
+6.7%

Weighted Avg Shares vs competitors

How ARVN compares with its peers on the latest reported figures

  • ARVN's LTM Mar 2026 weighted avg shares of 68.65M shares is the 5th highest of the 6 companies compared; the peer median is 91.85M shares.
  • Its year-over-year change of -4.9% is the lowest of 6, against a peer median of +16.0%.
  • Over three fiscal years its annual growth of +6.9% compares with a peer median of +19.3%.
ARVN Competitors Peer median
Weighted Avg Shares for ARVN and competitors
Company Period LTM YoY 3-year CAGR
NRIXNurix Therapeutics, Inc.LTM Aug 2026106.95M +29.6%+21.3%
CCCCC4 Therapeutics, Inc.LTM Mar 202696.61M +38.1%+19.3%
KYMRKymera Therapeutics, Inc.LTM Jun 202691.85M +16.0%+16.1%
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 202673.92M -0.4%+20.7%
ARVNArvinas, Inc.LTM Mar 202668.65M -4.9%+6.9%
FHTXFoghorn Therapeutics Inc.LTM Mar 202664.63M +7.9%+14.8%
Peer median (excluding ARVN) 91.85M+16.0%+19.3%

Competitors are the stored peer set for ARVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue53.6M131.4M78.5M263.4M262.6M
Cost of Revenue00005.2M
Gross Profit53.6M131.4M78.5M263.4M257.4M
Gross Margin100.0%100.0%100.0%100.0%98.0%
Research & Development180.4M315M379.7M348.2M282.9M
Selling, General & Admin61.6M79.6M100.3M165.4M89.4M
Operating Expenses242M394.6M480M513.6M372.3M
Depreciation & Amortization6M8.2M6.7M6.6M5.2M
EBITDA(184.9M)(253.4M)(359.7M)(191.7M)(75.3M)
EBITDA Margin-345.0%-192.8%-458.2%-72.8%-28.7%
Operating Income(188.4M)(263.2M)(401.5M)(250.2M)(114.9M)
Operating Margin-351.5%-200.3%-511.5%-95.0%-43.8%
Interest Income1.8M12M38.8M54.8M22M
Interest Expense100K0000
Other Income / Expenses(2.6M)1.6M35.1M51.9M34.4M
Income Before Tax(191M)(261.6M)(366.4M)(198.3M)(80.5M)
Pre-Tax Margin-356.3%-199.1%-466.8%-75.3%-30.7%
Income Tax Expense020.9M900K600K300K
Net Income(191M)(282.5M)(367.3M)(198.9M)(80.8M)
Net Margin-356.3%-215.0%-467.9%-75.5%-30.8%
EPS (Basic)(3.82)(5.31)(6.62)(2.77)(1.28)
EPS (Diluted)(3.82)(5.31)(6.62)(2.77)(1.28)
Weighted Avg Shares50M53.2M55.5M71.9M64.9M
Weighted Avg Shares (Diluted)50M53.2M55.5M71.9M64.9M

Arvinas, Inc.

NASDAQ:ARVN

Intrinsic Alpha fair value

Locked

Current Price

$6.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.